UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| $\mathbf{F}_{\mathbf{O}}$ | rm | 8- | K |
|---------------------------|----|----|---|
| 1 1/ | | | |

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 2, 2021

Commission File Number: 001-36568

HEALTHEQUITY, INC.

Delaware (State or other jurisdiction of incorporation or organization)

001-36568

(Commission File Number)

52-2383166 (I.R.S. Employer Identification Number)

15 West Scenic Pointe Drive Suite 100 Draper, Utah 84020 (801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant's Principal Executive Offices)

Not Applicable

(Former name or former address, if changed since last report)

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the belowing provisions (see General Instruction A.2): | | | | |
|---|-------------------|---|--|--|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | | | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | | | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | | | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | | | |
| ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company | | | | |
| f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | | | | |
| Securities registered pursuant to Section 12(b) of the Act: | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | |
| Common stock, par value \$0.0001 per share | HQY | The NASDAQ Global Select Market | | |
| | | | | |

Item 8.01 Other Events

On March 2, 2021, HealthEquity, Inc. (the "Company") consummated an additional closing of 750,000 shares of the Company's common stock pursuant to the exercise in full by the underwriter of its over-allotment option in the Company's previously announced offering. The gross proceeds to the Company from the sale of these shares are \$60,225,000. Such proceeds are in addition to the proceeds of \$401.5 million from the sale of shares in February.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.

By: /s/ Darcy Mott

Darcy Mott

Executive Vice President and Chief Financial Officer

Dated: March 2, 2021